hematologic disorders
Conditions
Interventions
Control group (Eltrombopag / Recombinant human thrombopoietin group):None
Romiplostim group:None
Sponsors
Zhejiang Provincial Hospital of TCM
Eligibility
Sex/Gender
All
Age
8 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Patients with hematologic disorders (benign or malignant; for malignant diseases, complete remission or partial remission should be achieved before transplantation) who underwent allogeneic hematopoietic stem cell transplantation (donor types include HLA-matched sibling, haploidentical, or unrelated donor). 2.Received romiplostim, eltrombopag, or recombinant human thrombopoietin (rhTPO) as a platelet-promoting agent after transplantation, with the regimen meeting the study definition. 3.Age =8 years and =70 years, both genders. 4.Complete clinical data available to retrieve primary outcome measures (time to platelet engraftment, platelet transfusion volume, etc.).
Exclusion criteria
Exclusion criteria: 1.Patients with malignant hematologic diseases who did not achieve CR (complete remission) before transplantation. 2.Premature discontinuation of TPO-RA therapy for other reasons after transplantation (e.g., severe adverse events, physician decision), with total treatment duration <7 days. 3.Concomitant use of two or more TPO-RA agents or other platelet-promoting drugs. 4.Severe missing data for key variables (e.g., date of platelet engraftment, survival status). 5.Receipt of a second hematopoietic stem cell transplantation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to platelet engraftment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Cumulative incidence of relapse;Chronic GVHD grade;CMV reactivation;Post transplant lymphoproliferative disease;Duration of severe thrombocytopenia;Total platelet transfusion volume;Complete platelet recovery rate (=100×10^9/L);Incidence of adverse events;Total red blood cell transfusion volume;Event free survival;EBV reactivation;Transplant related mortality;Time to neutrophil engraftment;Acute GVHD grade;Platelet engraftment rate (day +30);Neutrophil engraftment rate; | — |
Countries
China
Contacts
Public ContactXianfu Sheng
(Zhejiang Provincial Hospital of Traditional Chinese Medicine
Outcome results
None listed